1-2 of 2
Cécile Gouttefangeas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma

Markus W. Löffler, Stefania Gori, Francesco Izzo, Andrea Mayer-Mokler, Paolo A. Ascierto, Alfred Königsrainer, Yuk Ting Ma, Bruno Sangro, Sven Francque, Luisa Vonghia, Alessandro Inno, Antonio Avallone, Jörg Ludwig, Diego Duarte Alcoba, Christian Flohr, Katrin Aslan, Regina Mendrzyk, Heiko Schuster, Marco Borrelli, Danila Valmori, Tanguy Chaumette, Regina Heidenreich, Cécile Gouttefangeas, Greta Forlani, Maria Tagliamonte, Caterina Fusco, Roberta Penta, Mercedes Iñarrairaegui, Ulrike Gnad-Vogt, Carsten Reinhardt, Toni Weinschenk, Roberto S. Accolla, Harpreet Singh-Jasuja, Hans-Georg Rammensee, Luigi Buonaguro
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2555–2566.
https://doi.org/10.1158/1078-0432.CCR-21-4424
Published: 13 June 2022
View article titled, Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma
Open the PDF for Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

Trine Zeeberg Iversen, Lotte Engell-Noerregaard, Eva Ellebaek, Rikke Andersen, Stine Kiaer Larsen, Jon Bjoern, Claus Zeyher, Cécile Gouttefangeas, Birthe Moerk Thomsen, Bente Holm, Per thor Straten, Anders Mellemgaard, Mads Hald Andersen, Inge Marie Svane
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (1): 221–232.
https://doi.org/10.1158/1078-0432.CCR-13-1560
Published: 05 January 2014
View article titled, Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
Open the PDF for Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase in another window
Includes: Supplementary data